Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 16/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.49 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471346 | 0.85 | OPRD1 (0.60) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 | |
| SCHEMBL471699 | 0.83 | OPRD1 (0.48) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 | |
| SCHEMBL471572 | 0.82 | ACACB (0.41) | OPRD1KCNH2MRGPRX2XDHOPRK1 | |
| SCHEMBL467366 | 0.80 | OPRD1 (0.67) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL471284 | 0.79 | OPRD1 (0.50) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 | |
| SCHEMBL16315360 | 0.77 | OPRD1 (0.50) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 | |
| SCHEMBL16359059 | 0.77 | OPRD1 (0.51) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 | |
| SCHEMBL10258789 | 0.76 | OPRD1 (0.78) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 | |
| SCHEMBL471286 | 0.73 | OPRD1 (0.63) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL467355 | 0.71 | OPRD1 (0.72) | OPRD1KCNH2MRGPRX2OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399577-A1 | Use of N-containing spirocompounds for the enhancement of cognitive function | Adolor Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885MRGPRX2 678/4885 |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CHAT, GRIN2C, GRIN2A | OPRD1 981/4885KCNH2 1960/4885MRGPRX2 2493/4885 |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885MRGPRX2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.